# Lipolytic Effects of GH in Hypopituitary Patients in Vivo

> **NCT02782208** · NA · COMPLETED · sponsor: **University of Aarhus** · enrollment: 9 (actual)

## Conditions studied

- Hypopituitarism
- Insulin Resistance
- Endocrine System Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Pituitary Diseases
- Brain Diseases

## Interventions

- **DRUG:** Acipimox
- **DRUG:** Placebo
- **DRUG:** GH substitution
- **OTHER:** GH pause

## Key facts

- **NCT ID:** NCT02782208
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-10
- **Primary completion:** 2016-12-22
- **Final completion:** 2016-12-22
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782208, "Lipolytic Effects of GH in Hypopituitary Patients in Vivo". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02782208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*